If my muscle could talk: Myokines as a biomarker of frailty.
Aging
Disability
Exercise
Mobility
Sarcopenia
Journal
Experimental gerontology
ISSN: 1873-6815
Titre abrégé: Exp Gerontol
Pays: England
ID NLM: 0047061
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
04
07
2019
revised:
12
08
2019
accepted:
26
08
2019
pubmed:
2
9
2019
medline:
14
7
2020
entrez:
2
9
2019
Statut:
ppublish
Résumé
Frailty is a potentially reversible state of increased vulnerability to negative health-related outcomes that occurs as a result of multisystem biological impairment and environmental aspects. Given the relevance of this condition in both clinics and research, biomarkers of frailty have been actively sought after. Although several candidate biomarkers of frailty have been identified, none of them has yet been incorporated in the assessment or monitoring of the condition. Over the last years, increasing research interest has been focused on myokines, a set of cytokines, small proteins and proteoglycan peptides that are synthetized, expressed and released by skeletal myocytes in response to muscular contractions. Myokines may act in autocrine, paracrine, and endocrine manner and regulate several processes associated with physical frailty, including muscle wasting, dynapenia, and slowness. This review discusses the rationale to support the use of myokines as biomarkers of frailty in older adults.
Identifiants
pubmed: 31473199
pii: S0531-5565(19)30451-6
doi: 10.1016/j.exger.2019.110715
pii:
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
Muscle Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
110715Informations de copyright
Copyright © 2019. Published by Elsevier Inc.